Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 14/20 | 0.36 |
| ▸ | CDK1 | P06493 | 12/20 | 0.36 |
| ▸ | CDK6 | Q00534 | 9/20 | 0.36 |
| ▸ | PLK4 | O00444 | 3/20 | 0.35 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.35 |
| ▸ | CDK2 | P24941 | 3/20 | 0.35 |
| ▸ | CCNB1 | P14635 | 3/20 | 0.34 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.34 |
| ▸ | CCND3 | P30281 | 2/20 | 0.34 |
| ▸ | KDR | P35968 | 2/20 | 0.34 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.34 |
| ▸ | CIT | O14578 | 1/20 | 0.34 |
| ▸ | GAK | O14976 | 1/20 | 0.34 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.34 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.34 |
| ▸ | STK16 | O75716 | 1/20 | 0.34 |
| ▸ | CCNK | O75909 | 1/20 | 0.34 |
| ▸ | STK10 | O94804 | 1/20 | 0.34 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.34 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2511865 | 1.00 | CDK4 (0.36) | CDK4CDK1CDK6PLK4IRAK4 | |
| SCHEMBL18288741 | 0.88 | CDK4 (0.36) | CDK4CDK1CDK6IRAK4CDK2 | |
| SCHEMBL22272299 | 0.87 | IRAK4 (0.36) | IRAK4LPLLIPG | |
| SCHEMBL30926519 | 0.84 | LPL (0.31) | IRAK4LPLLIPG | |
| SCHEMBL21522780 | 0.84 | CDK4 (0.40) | CDK4CDK6IRAK4CCND3CCND1 | |
| SCHEMBL21522812 | 0.84 | CDK4 (0.40) | CDK4CDK6IRAK4CCND3CCND1 | |
| SCHEMBL21522778 | 0.84 | CDK4 (0.40) | CDK4CDK6IRAK4CCND3CCND1 | |
| SCHEMBL20987201 | 0.84 | LPL (0.31) | IRAK4EGFRLPLLIPG | |
| SCHEMBL22172152 | 0.84 | KMT2A (0.33) | CDK4CDK6IRAK4CCND3CCND1 | |
| SCHEMBL19836734 | 0.84 | ROCK1 (0.32) | CDK4CDK6IRAK4CCND3CCND1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4626423-A1 | CDK INHIBITORS AND METHODS AND USE THEREOF | Relay Therapeutics, Inc. (US) | 2025-10-08 | — | — | EP | disclosed |
| EP-4592286-A1 | MACROCYCLIC NITROGEN-CONTAINING CROWN ETHER COMPOUND AND USE THEREOF AS PROTEIN KINASE INHIBITOR | Artivila Biopharma (CN) | 2025-07-30 | — | — | EP | disclosed |
| EP-4565588-A1 | BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF | Suzhou Keen Therapeutics Co., Ltd. (CN) | 2025-06-11 | — | — | EP | disclosed |
| WO-2024256569-A1 | NOVEL CDK DEGRADERS | RIJKSUNIVERSITEIT GRONINGEN (NL) | 2024-12-19 | — | — | WO | disclosed |
| US-20240408169-A1 | CYCLIN INHIBITORS | CIRCLE PHARMA, INC. | 2024-12-12 | — | — | US | disclosed |
| WO-2024220866-A1 | NOVEL AMINOPYRIMIDINE DERIVATIVES AS CYCLIN-DEPENDENT KINASE INHIBITORS | ACCUTAR BIOTECHNOLOGY INC. (US) | 2024-10-24 | — | — | WO | disclosed |
| WO-2024173646-A1 | CYCLIN-DEPENDENT KINASE DEGRADING COMPOUNDS | INNOVO THERAPEUTICS, INC. (US) | 2024-08-22 | — | — | WO | disclosed |
| WO-2024119122-A1 | CDK INHIBITORS AND METHODS AND USE THEREOF | RELAY THERAPEUTICS, INC. (US) | 2024-06-06 | — | — | WO | disclosed |
| WO-2023241620-A1 | BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF | SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) | 2023-12-21 | — | — | WO | disclosed |
| EP-3492462-B1 | AMINO PYRIMIDINE COMPOUND FOR INHIBITING PROTEIN TYROSINE KINASE ACTIVITY | SHENZHEN TARGETRX INC (CN) | 2023-08-30 | — | — | EP | disclosed |
| CN-115057845-A | Preparation method of Abelide | 山东罗欣药业集团恒欣药业有限公司 | 2022-09-16 | — | — | CN | disclosed |
| WO-2022166916-A1 | SUBSTITUTED HETEROARYL DERIVATIVE, AND COMPOSITION AND USE THEREOF | 深圳市塔吉瑞生物医药有限公司 | 2022-08-11 | — | — | WO | disclosed |
| CN-114874189-A | Substituted heteroaryl derivatives, compositions and uses thereof | 深圳市塔吉瑞生物医药有限公司 | 2022-08-09 | — | — | CN | disclosed |
| CN-112225724-B | Benzimidazole compound kinase inhibitor and preparation method and application thereof | 江苏豪森药业集团有限公司 | 2022-04-29 | — | — | CN | disclosed |
| CN-112250669-B | Benzimidazole compound kinase inhibitor and preparation method and application thereof | 江苏豪森药业集团有限公司 | 2022-02-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240408169-A1 | CYCLIN INHIBITORS | CCNI, CDK2, CDK1 | CDK4 7/4885CDK1 3/4885CDK6 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.